Saturday, August 31, 2019

Immunization Works August 2019 Newsletter | CDC

Immunization Works August 2019 Newsletter | CDC

Immunization Works August 2019

Immunization Works Newsletter August 2019

Top Stories

Vaccine Information Statements (VISs): Updated VISs for live, attenuated influenza (LAIV), inactivated influenza, meningococcal ACWY, meningococcal B, MMR, MMRV, varicella, hepatitis B, and Japanese encephalitis vaccines have been posted on the VIS website. We encourage providers to begin using these VISs immediately, but stocks of the previous editions may be used until exhausted. For more information and to view the VISs please visit the VIS website.
2019 Pink Book Webinar Series: CDC is offering a weekly series of 15 one-hour webinars that provide an overview of vaccination principles, general recommendations, immunization strategies, and specific information about vaccine-preventable diseases and the vaccines that prevent them. Each webinar explores a chapter from the 13th edition of Epidemiology and Prevention of Vaccine-Preventable Diseases (the Pink Book) and also includes updated information from recent Advisory Committee on Immunization Practices (ACIP) meetings and votes. The webinars started June 5, 2019, and will air live most Wednesdays from 12–1 p.m. EDT through September 25, 2019. Please visit the Pink Book webinar web page for the schedule and additional information. Continuing Education (CE) will be available for each event.

Influenza

Flu Information and Resources:
As you prepare to have conversations with patients about flu vaccination, CDC has pulled together a suite of digital and print-off materials to help in effectively conveying the threat of flu and why flu vaccination is so important.
These resources include:
We have updated this web page and related social media images and messages to reflect the upcoming flu season. You can also find a suite of public-focused educational materials here.
#WhyIFightFlu
CDC is currently collecting a variety of Flu Fighter profiles through partners that describe how members of the American public have been affected by flu and why they fight the often devastating disease. We are aiming to post these profiles after the annual flu vaccination season kickoff press conference, which will be hosted by NFID on September 26, 2019.
This hashtag campaign is focused on reinforcing the negative impact of flu and positive benefits of flu vaccination. we invite all of our partners to use the hashtag #WhyIFightFlu and share an answer to the question, “why do you fight flu?” as we move forward into flu season.
Additional Resources
Save the Date
  • September 26, 2019: Watch and promote the livestream of the annual flu vaccination season kickoff press conference hosted by the National Foundation for Infectious Diseases (NFID). Link will be shared closer to the kickoff.
  • December 1–7, 2019: Join CDC in promoting flu vaccination before and during National Influenza Vaccination Week (NIVW). NIVW-specific updates, events, and resources will be posted on CDC’s NIVW web site.
  • TBD: Webinar focused on talking through the many different flu vaccines for the 2019–20 flu season and making a strong flu vaccine recommendation, tentatively set for early October
  • Throughout flu season: We will be sharing stories of why members of the American public fight flu with the hashtag #WhyIFightFlu
Projected Population Benefit of Increased Effectiveness and Coverage of Influenza Vaccination on Influenza Burden: A study published July 25 in Clinical Infectious Diseases used mathematical modeling to show how increases in influenza vaccine effectiveness or vaccination coverage would result in substantial reductions to influenza-associated illnesses in the U.S. The authors looked at a variety of influenza seasons, ranging in severity of activity. The authors found that, during the 2017–18 high-severity flu season, a 5% absolute increase in vaccine effectiveness (VE) would have prevented an additional 1,050,000 illnesses and 25,000 hospitalizations. They also found that a 5% absolute increase in overall vaccination coverage would have prevented an additional 785,000 illnesses (56% among those age 18–64 years) and 11,000 hospitalizations. In summary, small, attainable improvements in influenza vaccine effectiveness or vaccination coverage could lead to substantial additional reductions of influenza burden in the U.S. The article was written by Michelle Hughes, Carrie Reed, Brendan Flannery, Shikha Garg, Alicia Fry, and Melissa Rolfes of CDC’s Influenza Division, and James Singleton of CDC’s Immunization Services Division. You can read more hereexternal icon.

MMWR

National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Age 13–17 Years in the U.S., 2018: ACIP recommends routine vaccination of persons age 11–12 years with human papillomavirus (HPV) vaccine, quadrivalent meningococcal conjugate vaccine (MenACWY), and tetanus and reduced diphtheria toxoids and acellular pertussis vaccine (Tdap). A booster dose of MenACWY is recommended at age 16 years, and catch-up vaccination is recommended for hepatitis B vaccine (HepB), measles, mumps, and rubella vaccine (MMR), and varicella vaccine (VAR) for adolescents whose childhood vaccinations are not up to date.
In 2018, 51.1% of adolescents age 13–17 years were up to date with the HPV vaccine series, and 68.1% had received more than 1 dose of HPV vaccine. During 2017–2018, the increase in HPV vaccination coverage was attributable to increases among males only (increase of 4.4 percentage points in males who were up to date versus 0.6 in females). Coverage with more than 1 MenACWY dose increased by 1.5 percentage points to 86.6%. Among persons age 17 years, coverage with more than 2 MenACWY doses increased by 6.5 percentage points to 50.8%. Coverage with more than 1 dose of MenB among persons age 17 years was 17.2% (95% confidence interval=14.9%–19.9%). No significant increases were observed for coverage with more than 3 hepatitis B doses; more than 2 measles, mumps, and rubella vaccine doses; and more than 1 and more than 2 varicella vaccine doses among adolescents without a history of varicella disease. Please read the August 23 MMWR for the full report.
Human Papillomavirus Vaccination (HPV) for Adults: Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP): Vaccination against HPV is recommended to prevent new HPV infections and HPV-associated diseases, including some cancers. ACIP routinely recommends HPV vaccination at age 11 or 12 years; vaccination can be given starting at age 9 years. Catch-up vaccination has been recommended since 2006 for females through age 26 years and since 2011 for males through age 21 years and certain special populations through age 26 years. The August 16 MMWR updates ACIP catch-up HPV vaccination recommendations and guidance published in 2014, 2015, and 2016. Routine recommendations for vaccination of adolescents have not changed. In June 2019, ACIP recommended catch-up HPV vaccination for all persons through age 26 years. ACIP did not recommend catch-up vaccination for all adults age 27 through 45 years, but recognized that some persons in this age range who are not adequately vaccinated might be at risk for new HPV infection and might benefit from vaccination. Therefore, ACIP recommended shared clinical decision-making regarding potential HPV vaccination for these persons.

Resources and Information

Immunization Quality Improvement for Providers (IQIP): On July 1, 2019, IQIP replaced Assessment, Feedback, Incentives, and eXchange (AFIX) as CDC’s national immunization quality improvement program. IQIP promotes and supports the implementation of VFC provider-level immunization quality improvement strategies designed to increase vaccine uptake among children and adolescents in adherence to the routine schedule recommended by the Advisory Committee on Immunization Practices (ACIP). Visit the IQIP website for additional information.
Pediatricians Answer Parent’s HPV Vaccine Questions in New “Can I Ask You a Question” Videos: CDC’s new “Can I Ask You a Question” video series for parents is now available for viewing. In the series, real pediatricians use their expertise to answer parents’ questions about the HPV vaccine and why it’s important for preventing cancer. The videos feature pediatricians answering friends’ questions about the HPV vaccine in a casual setting and reflect some of the most common questions parents have about the HPV vaccine.
You can find all the videos on the CDC website and on YouTube. You can find a Spanish version of one of these videos on YouTube, too.
Nominations Open for 2019 HPV Vaccine is Cancer Prevention Champion Award: CDC, the American Cancer Society, and the American Association of Cancer Institutes are partnering for the third annual “HPV Vaccine is Cancer Prevention Champion” Award. The Champion award recognizes clinicians, clinics, practices, groups, and health systems that are going above and beyond to foster HPV vaccination among adolescents in their communities. The award recognizes up to one champion from each of the 50 U.S. states, 8 U.S. territories and freely associated states, and the District of Columbia. Recognize a deserving health care professional in your state by nominating them for the award. Learn more about the award and how to submit a nomination by visiting the “HPV is Cancer Prevention Champion” Award website, or send an e-mail to preteenvaccines@cdc.gov.
Epidemiology and Prevention of Vaccine-Preventable Diseases, 13th Edition (the Pink Book): Published by CDC, NCIRD, and the Public Health Foundation (PHF), the Pink Book provides health care professionals with the most comprehensive information available on vaccines and vaccine-preventable diseases. The Pink Book is available for purchase from the PHF Learning Resource Centerexternal icon, and the chapters and appendices can be viewed or downloaded from the NCIRD vaccines site.
“Keys to Storing and Handling Your Vaccine Supply” Video: Two of the most important safeguards for the nation’s vaccine supply are proper vaccine storage and handling. An updated web-on-demand video, titled “Keys to Storing and Handling Your Vaccine Supply,” is designed to decrease vaccine storage and handling errors by demonstrating recommended best practices and addressing frequently asked questions. Continuing Education (CE) is available.
Vaccine Administration e-Learn: An e-Learn on vaccine administration is now available. Proper vaccine administration is critical for ensuring that vaccines are both safe and effective. Vaccine administration errors happen more often than you might think. Of the average 36,000 reports received annually by the Vaccine Adverse Event Reporting System (VAERS)external icon, about 1,500 are directly related to administration error. Some of the most common vaccine administration errors include:
  • Not following the recommended immunization schedule
  • Administering improperly stored or expired vaccine and/or diluent
  • Administering the wrong vaccine—confusing look-alike or sound-alike vaccines such as DTaP/Tdap or administering products outside age indications
The e-Learn is a free, interactive, online educational program that serves as a useful introductory course or a great refresher on vaccine administration. The self-paced e-Learn provides comprehensive training, using videos, job aids, and other resources to accommodate a variety of learning styles, and offers a certificate of completion and/or Continuing Education (CE) for those that complete the training.
For more information, please contact nipinfo@cdc.gov.
Current Issues in Immunization NetConferences: Immunization netconferences are live, one-hour events combining an online visual presentation with simultaneous audio via telephone conference call, along with a live question-and-answer session. Registration, Internet access, and a separate phone line are needed to participate. Please visit the netconference web page for additional information and to view archived webcasts.
You Call the Shots Modules: You Call the Shots is a series of interactive, web-based training courses developed through the Project to Enhance Immunization Content in Nursing Education and Training. These courses are ideal for medical or nursing students, new vaccination providers, or seasoned health care providers seeking a review. Please visit the You Call the Shots web page to view all the modules. Continuing Education (CE) is available for viewing a module and completing an evaluation.
Measles and Mumps Resources: CDC aims to continue increasing awareness of measles and mumps among individuals and families and to encourage MMR vaccination. To support disease prevention and vaccination educational efforts, CDC has developed a variety of measles and mumps resources, including fact sheets, podcasts, and matte articles. Some of the measles graphics are also available in Spanish.
CDC and Medscape: This special series of commentariesexternal icon, part of a collaboration between CDC and Medscape, is designed to deliver CDC’s authoritative guidance directly to Medscape’s physicians, nurses, pharmacists, and other health care providers. In this series, CDC experts offer video commentaries on current topics important to practicing clinicians. NCIRD has contributed to a variety of commentaries. You will need to sign up and log in as a member to view the commentaries and registration is free.
Immunization Resources: Various publications are available for ordering at CDC-INFO On Demand. You can search for immunization publications by using the “Programs” drop-down menu and selecting “Immunization and Vaccines,” or you can search by “Title.” The 2019 recommended immunization schedules are available for ordering.
CDC Job Openings: CDC is committed to recruiting and hiring qualified candidates for a wide range of immunization and other positions. Researchers, medical officers, epidemiologists, and other specialists are often needed to fill positions within CDC. For a current listing, including international opportunities, please visit CDC’s employment web page.

Calendar of Events

VFC Annual Immunization Reviewexternal icon, Tennessee Immunization Program, September 19, 20, 24, and 25, 2019, various cities in Tennessee
Nevada Health Conferenceexternal icon, Immunize Nevada, October 14–15, 2019, Las Vegas, NV
Texas Immunization Conferenceexternal icon, Texas DSHS, October 23–25, 2019, Addison, TX
ACIP Meeting, October 23–24, 2019, Atlanta, GA
Ohio Immunization Conferenceexternal icon, Immunize Ohio, November 6, 2019, Wadsworth, OH
National Conference for Immunization Coalitions and Partnerships (NCICP)external icon, Hawaii Immunization Coalition and the Hawaii Public Health Institute, November 13–15, 2019, Honolulu, HI
Clinical Vaccinology Courseexternal icon, National Foundation for Infectious Diseases (NFID), November 16–17, 2019, Washington, D.C.

Preparing for a Hurricane or Tropical Storm | Features | CDC

Preparing for a Hurricane or Tropical Storm | Features | CDC



Preparing for a Hurricane or Tropical Storm

Satellite view of the eye of a hurricane
You can’t stop a tropical storm or hurricane, but you can take steps now to protect you and your family.
If you live in areas at risk, the Centers for Disease Control and Prevention (CDC) encourages you to be prepared for hurricane season. The Atlantic hurricane season is June 1 through November 30 each year.
Please follow these important hurricane preparedness tips from CDC:
After you have read these tips, please review the other resources available on the CDC Hurricaneswebsite. You can also check out CDC’s new reference document that contains key messages on hurricane and flood related health threats. The Preparedness and Safety Messaging for Hurricanes, Flooding, and Similar Disasters pdf icon[1.18 MB] resource can help local responders quickly create and adapt health communication products for affected communities. The document contains messages on various topics including food safety, carbon monoxide poisoning, waterborne diseases, and mold.
CDC strongly recommends that you print all-important resources before a hurricane strikes. Power outages during and after a hurricane can prevent you from accessing information online when you most need it. Preparing now can help keep you and your family safe.

Healthy Food Choices Made Easy

Healthy Food Choices Made Easy

Home

08/29/2019 12:26 PM EDT


Source: American Diabetes Association
Related MedlinePlus Pages: Diabetic Diet

How Will This Impact My Baby

How Will This Impact My Baby

Home

08/29/2019 12:17 PM EDT


Source: American Diabetes Association
Related MedlinePlus Pages: Diabetes and Pregnancy

Blood Sugar Testing and Control

Blood Sugar Testing and Control

Home



08/29/2019 12:58 PM EDT


Source: American Diabetes Association
Related MedlinePlus Pages: Blood SugarDiabetes Complications

Nutrition Overview

Nutrition Overview

Home

08/29/2019 12:41 PM EDT


Source: American Diabetes Association
Related MedlinePlus Pages: Diabetic Diet

What Are My Options?

What Are My Options?

Home



08/29/2019 01:59 PM EDT


Source: American Diabetes Association
Related MedlinePlus Pages: Diabetes Medicines

Steps to Prevent or Delay Nerve Damage

Steps to Prevent or Delay Nerve Damage

Home

08/29/2019 01:54 PM EDT


Source: American Diabetes Association
Related MedlinePlus Pages: Diabetes ComplicationsDiabetic Foot

Paying for Medical Care | USAGov

Paying for Medical Care | USAGov

MedlinePlus



08/29/2019 03:47 PM EDT


Source: General Services Administration
Related MedlinePlus Pages: Financial AssistanceHealth Insurance

Prepare Your Health | CDC

Prepare Your Health | CDC

Man holding a childs hand



September is National Preparedness Month, when all Americans are encouraged to focus on preparing for emergencies, including making plans to protect their health.

There are many reasons to prepare your health for an emergency. They start with your family and friends and extend to your neighbors and community at large. But most Americans don't have supplies set aside or plans in place to protect themselves or their family’s health and safety in the event of a natural disaster.

The good news is that it's never too late to prepare for a public health emergency. You can take actions, make healthy choices, and download free resources to help you prepare for, adapt to, and cope with adversity.
Learn how to prepare for, respond to, and recover from emergencies, then share what you’ve learned with others to help build more resilient communities.

CDC Health Alert Network (HAN) Health Advisory: Severe Pulmonary Disease Associated with Using E-Cigarette Products

HAN Archive - 00421 | Health Alert Network (HAN)
Health Alert Network logo.

Severe Pulmonary Disease Associated with Using E-Cigarette Products

This is an official CDC Health Advisory

Distributed via the CDC Health Alert Network
August 30, 2019, 0935 AM ET (9:35 AM ET)
CDCHAN-00421
Summary
The Centers for Disease Control and Prevention (CDC) is providing: 1) background information on the forms of e-cigarette products, 2) information on the multistate outbreak of severe pulmonary disease associated with using e-cigarette products (devices, liquids, refill pods, and cartridges), and 3) clinical features of patients with severe pulmonary disease. This health advisory also provides recommendations for clinicians, public health officials, and the public based on currently available information.
General Background
E-cigarettes typically contain nicotine, most also contain flavorings and other chemicals, and some may contain marijuana or other substances. They are known by many different names and come in many shapes, sizes and device types. Devices may be referred to as “e-cigs,” “vapes,” “e-hookahs,” “vape pens,” “mods,” tanks, or electronic nicotine delivery systems (ENDS). Some e-cigarette devices resemble other tobacco products such as cigarettes; some resemble ordinary household items such as USB flash drives, pens, and flashlights; and others have unique shapes. Use of e-cigarettes is sometimes referred to as “vaping” or “juuling.” E-cigarettes used for dabbing are sometimes called “dab” pens.
E-cigarettes can contain harmful or potentially harmful substances, including nicotine, heavy metals (e.g., lead), volatile organic compounds, and cancer-causing chemicals. Additionally, some e-cigarette products are used to deliver illicit substances; may be acquired from unknown or unauthorized (i.e., “street”) sources; and may be modified for uses that could increase their potential for harm to the user. For example, some e-cigarette pods or cartridges marketed for single use can be refilled with illicit or unknown substances. In addition, some e-cigarette products are used for “dripping” or “dabbing.” Dripping involves dropping e-cigarette liquid directly onto the hot coils of an e-cigarette which can result in high concentrations of compounds (e.g., tetrahydrocannabinol [THC] and cannabinoid compounds). Dabbing involves superheating substances such as “budder”, butane hash oil (BHO), and “710” that contain high concentrations of THC and other plant compounds (e.g., cannabidiol [CBD]).
Youth, young adults, pregnant women, as well as adults who do not currently use tobacco products should not use e-cigarettes. E-cigarettes containing nicotine have the potential to help some individual adult smokers reduce their use of and transition away from cigarettes. However, e-cigarettes are not currently approved by the Food and Drug Administration (FDA) as a quit smoking aid, and the available science is inconclusive on whether e-cigarettes are effective for quitting smoking.
Outbreak Background
As of August 27, 2019, 215 possible cases have been reported from 25 states and additional reports of pulmonary illness are under investigation. One patient (in Illinois) with a history of recent e-cigarette use was hospitalized with severe pulmonary disease and subsequently died. Although the etiology of e-cigarette-associated pulmonary disease is undetermined, epidemiologic investigations in affected states are ongoing to better characterize the exposures, demographic, clinical, and laboratory features and behaviors of patients. All patients have reported using e-cigarette products. The exact number is currently unknown, but many patients have reported using e-cigarettes containing cannabinoid products such as THC or CBD.
Based on reports from several states, patients have experienced respiratory symptoms (cough, shortness of breath, or chest pain), and some have also experienced gastrointestinal symptoms (nausea, vomiting, or diarrhea) or non-specific constitutional symptoms (fatigue, fever, or weight loss). Symptoms typically develop over a period of days but sometimes can manifest over several weeks. Gastrointestinal symptoms sometimes preceded respiratory symptoms. Fever, tachycardia, and elevated white blood cell count have been reported in the absence of an identifiable infectious disease. Many patients have sought initial care in ambulatory settings, some with several visits, before hospital admission.
Radiologic findings have varied and are not present in all patients upon initial presentation. Bilateral pulmonary infiltrates and diffuse ground-glass opacities have been reported. Many patients required supplemental oxygen, some required assisted ventilation and oxygenation, and some were intubated. Some patients have been treated with corticosteroids with demonstrated improvement. Antimicrobial therapy alone has not consistently been associated with clinical improvement. Assessment for infectious etiologies has been completed in many patients without an identified infectious cause. Several patients from one state have been diagnosed with lipoid pneumonia based on clinical presentation and detection of lipids within bronchoalveolar lavage samples stained specifically to detect oil.
All patients have reported using e-cigarette products and the symptom onset has ranged from a few days to several weeks after e-cigarette use.  Within two states, recent inhalation of cannabinoid products, THC or cannabidiol, have been reported in many of the patients. To date, no single substance or e-cigarette product has been consistently associated with illness. CDC is working closely with state health departments to facilitate collecting product specimens for testing at the U.S. FDA Forensic Chemistry Center.
Recommendations for Clinicians
  1. Report cases of severe pulmonary disease of unclear etiology and a history of e-cigarette product use within the past 90 days to your state or local health department. Reporting of cases may help CDC and state health departments determine the cause or causes of these pulmonary illnesses.
  2. Ask all patients who report e-cigarette product use within the last 90 days about signs and symptoms of pulmonary illness.
  3. If e-cigarette product use is suspected as a possible etiology of a patient’s severe pulmonary disease, obtain detailed history regarding:
    • Substance(s) used: nicotine, cannabinoids (e.g., marijuana, THC, THC concentrates, CBD, CBD oil, synthetic cannabinoids [e.g., K2 or spice], hash oil, Dank vapes), flavors, or other substances
    • Substance source(s): commercially available liquids (i.e., bottles, cartridges, or pods), homemade liquids, and re-use of old cartridges or pods with homemade or commercially bought liquids
    • Device(s) used: manufacturer; brand name; product name; model; serial number of the product, device, or e-liquid; if the device can be customized by the user; and any product modifications by the user (e.g., exposure of the atomizer or heating coil)
    • Where the product(s) were purchased
    • Method of substance use: aerosolization, dabbing, or dripping
    • Other potential cases: sharing e-cigarette products (devices, liquids, refill pods, or cartridges) with others
  4. Determine if any remaining product, including devices and liquids, are available for testing. Testing can be coordinated with the local or state health departments.
  5. Consider all possible causes of illness in patients reporting respiratory and gastrointestinal symptoms and of e-cigarette product use. Evaluate and treat for other possible causes of illness (e.g., infectious, rheumatologic, neoplastic) as clinically indicated. Consider consultation with specialists (pulmonary, infectious disease, critical care, medical toxicology) as appropriate.
  6. Clinical improvement of patients with severe pulmonary disease associated with e-cigarette use has been reported with the use of corticosteroids. The decision to use corticosteroids should be made on a case-by-case basis based on risks and benefits and the likelihood of other etiologies.
  7. Lipoid pneumonia associated with inhalation of lipids in aerosols generated by e-cigarettes has been reported based on the detection of lipid-laden alveolar macrophages obtained by bronchoalveolar lavage (BAL) and lipid staining (e.g., oil red O). The decision about whether to perform a BAL should be based on individual clinical circumstances.
  8. Lung biopsies have been performed on some patients. If a lung biopsy is obtained, lipid staining may be considered during pathologic examination, and is best performed on fresh tissue. Routine pathology tissue processing (including formalin-fixation and paraffin-embedding) can remove lipids. Conducting routine tissue processing and histopathologic evaluation is still important. Consider consultation with specialists in pulmonary medicine and pathology to help inform any evaluation plan.
  9. Patients who have received treatment for severe pulmonary disease related to e-cigarette product use should undergo follow-up evaluation as clinically indicated to monitor pulmonary function.
Recommendations for Public Health Officials
  1. State public health officials should promptly notify CDC about possible cases via VapingAssocIllness@cdc.gov.
  2. Contact CDC at VapingAssocIllness@cdc.gov for case classification criteria, reporting guidelines, case investigation forms, and questions about this outbreak.
  3. Consider conducting case-finding activities that use existing data sources (e.g., local poison control center, coroner and medical examiner’s office, and other applicable surveillance systems including syndromic surveillance). CDC has developed two working syndromic surveillance definitions (one version with specific symptoms and a second focused on e-cigarette product use). CDC will be programming these definitions in CDC’s National Syndromic Surveillance Program’s BioSense/ESSENCE platform for case-finding within the platform.
  4. Consider asking the medical examiner or coroner’s office and other pathologists to report possible cases, especially those without an alternative, likely diagnosis. If individuals are identified after death or at autopsy who showed signs of severe pulmonary disease as described above, medical examiners and coroners are encouraged to report the cases to their local or state health department. Thorough sampling of trachea, bronchi, and lung parenchyma with collection of fresh lung tissue for staining of lipids (e.g., oil red O) and submission of formalin-fixed, paraffin-embedded tissues for routine histopathology are recommended. For further consultation, public health officials can contact CDC’s Infectious Diseases Pathology Branch at pathology@cdc.gov.
  5. State health department officials seeking technical assistance with an epidemiologic investigation can contact CDC at VapingAssocIllness@cdc.gov. State health department officials seeking technical assistance with laboratory testing can discuss with their state health department laboratories or contact CDC at VapingAssocIllness@cdc.gov.
Recommendations for the Public
  1. While this investigation is ongoing, if you are concerned about these specific health risks, consider refraining from using e-cigarette products.
  2. Regardless of the ongoing investigation, anyone who uses e-cigarette products should not buy these products off the street (e.g., e-cigarette products with THC, other cannabinoids) and should not modify e-cigarette products or add any substances to these products that are not intended by the manufacturer.
  3. Regardless of the ongoing investigation, e-cigarette products should not be used by youth, young adults, pregnant women, as well as adults who do not currently use tobacco products. If you use e-cigarette products, monitor yourself for symptoms (e.g., cough, shortness of breath, chest pain) and promptly seek medical attention if you have concerns about your health. CDC and FDA will continue to advise and alert the public as more information becomes available.
  4. Adult smokers who are attempting to quit should use evidence-based treatments, including counseling and FDA-approved medications. If you who need help quitting tobacco products, including e-cigarettes, contact your doctor.
  5. If you are concerned about harmful effects from e-cigarette products, call your local poison control center at: 1-800-222-1222.
  6. We encourage the public to submit detailed reports of any unexpected tobacco or e-cigarette-related health or product issues to the FDA via the online Safety Reporting Portal: https://www.safetyreporting.hhs.govexternal icon.
For More Information
References
Barrington-Trimis JL, Samet JM, McConnell RFlavorings in electronic cigarettes: an unrecognized respiratory health hazard? JAMA. 2014;312(23):2493-4. https://jamanetwork.com/journals/jama/fullarticle/1935097external icon
Behar RZ, Davis B, Wang Y, Bahl V, Lin S, Talbot PIdentification of toxicants in cinnamon-flavored electronic cigarette refill fluids. Toxicol In Vitro. 2014;28(2):198-208. https://www.ncbi.nlm.nih.gov/pubmed/24516877external icon
Flower M, Nandakumar L, Singh M, Wyld D, Windsor M, Fielding DRespiratory bronchiolitis-associated interstitial lung disease secondary to electronic nicotine delivery system use confirmed with open lung biopsy. Respirol Case Rep. 2017;5(3):e00230. https://onlinelibrary.wiley.com/doi/full/10.1002/rcr2.230external icon
Gerloff J, Sundar IK, Freter R, Sekera ER, Friedman AE, Robinson R, et al. Inflammatory Response and Barrier Dysfunction by Different e-Cigarette Flavoring Chemicals Identified by Gas Chromatography-Mass Spectrometry in e-Liquids and e-Vapors on Human Lung Epithelial Cells and Fibroblasts. Appl In Vitro Toxicol. 2017;3(1):28-40. https://www.liebertpub.com/doi/10.1089/aivt.2016.0030external icon
He T, Oks M, Esposito M, Steinberg H, Makaryus M“Tree-in-Bloom”: Severe Acute Lung Injury Induced by Vaping Cannabis Oil. Ann Am Thorac Soc. 2017;14(3):468-70. https://www.atsjournals.org/doi/10.1513/AnnalsATS.201612-974LEexternal icon
Khan MS, Khateeb F, Akhtar J, Khan Z, Lal A, Kholodovych V, et al. Organizing pneumonia related to electronic cigarette use: A case report and review of literature. Clin Respir J. 2018;12(3):1295-9. https://onlinelibrary.wiley.com/doi/abs/10.1111/crj.12775external icon
Kosmider L, Sobczak A, Prokopowicz A, Kurek J, Zaciera M, Knysak J, et al. Cherry-flavoured electronic cigarettes expose users to the inhalation irritant, benzaldehyde. Thorax. 2016;71(4):376-7. https://thorax.bmj.com/content/71/4/376external icon